Next Day Disclosure Returns - [Share Buyback]

Ascletis Pharma Inc. operates as a biotechnology company. The Company develops and discovers anti-viral drugs to address unmet medical needs in anti-viral, cancer, and fatty liver disease. Ascletis Pharma offers its services worldwide.

Next Day Disclosure Return

Announcements and Notices - [Other - Business Update]

Voluntary Announcement - Ascletis Selects Its First Oral Glp-1r/Gipr/Gcgr Triple Peptide Agonist, Asc37, For Clinical Development

Voluntary Announcement - Ascletis Announces Co-Formulation Of Asc36, Once-Monthly
Next-Generation Amylin Receptor Agonist And
Asc35, Once-Monthly Next-Generation Glp-1r/Gipr Dual
Agonist For Clinical Development

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Next Day Disclosure Return

Next Day Disclosure Return

Voluntary Announcement - Ascletis Selects Its First Oral Glp-1r/Gipr/Gcgr Triple Peptide Agonist, Asc37, For Clinical Development

Voluntary Announcement - Ascletis Announces Co-Formulation Of Asc36, Once-Monthly Next-Generation Amylin Receptor Agonist And Asc35, Once-Monthly Next-Generation Glp-1r/Gipr Dual Agonist For Clinical Development

Next Day Disclosure Return